Connect with us

Business

Aurora Cannabis stock still sliding

Published

 on

Shares in Aurora Cannabis Inc. continued to fall on Tuesday as the company confirmed that it asked key executive Cam Battley late last week to step down as chief corporate officer.

The Edmonton-based pot provider’s shares were down 5.6 per cent or 15 cents to $2.50 on the Toronto Stock Exchange early Tuesday.

On Monday, they fell almost 10 per cent as the market absorbed news released late Saturday that Battley, who has often been the public face of the company for investors, would immediately step down.

 

The Saturday release didn’t say why Battley was leaving but an emailed statement on Tuesday said Battley was asked last Friday to “step away” from his role as part of the evolution of the company’s leadership strategy.

In the earlier release, Aurora CEO Terry Booth wished Battley well in Australia — the release noted Australian authorities had approved his appointment as a director for MedReleaf Australia, a private medical cannabis company in which Aurora has a 10 per cent stake as well as 50 per cent voting rights.

Analysts have blamed recent steep declines in cannabis company shares on falling recreational sales in Canada due to high inventory levels, noting the market hasn’t grown as much as expected since recreational pot became legal in 2018.

“As a leader in the expanding global cannabis sector, Aurora continues to evolve the company to address the conditions of the industry and the company’s leadership ambitions in Canada and the U.S.,” said the email supplied by Jon Filson, senior manager of corporate communications.

“This includes changes to the leadership of the company with the departure of chief corporate officer, Cam Battley, who was asked to step away from his role on Dec. 20, 2019.”

Source link

Business

What side effects do Canadians report after getting COVID-19 vaccine? – News 1130

Published

 on


VANCOUVER (NEWS 1130) – B.C. is ramping up its vaccine efforts in the coming weeks, planning to get more people immunized faster by extending the length of time between first and second doses. That means you may be able to get the jab sooner that first thought.

So what has the experience been like for the many people who have already been vaccinated?

Looking at the latest poll from Leger, there is a range of experiences reported.

In Canada, most of those immunized against COVID-19 so far (55 per cent) have received the Pfizer vaccine. When it comes to side effects, respondents most commonly report pain in the arm, at 68 per cent.

About a quarter report tiredness and fewer than two-in-10 say they got a headache after rolling up their sleeve.

In descending order, other reported effects from the COVID-19 shot include muscle soreness, swelling, chills, and fever.

Only about three per cent report they were hospitalized, though the poll doesn’t go into why.

There is a significant portion of those polled who say they had absolutely no side effects at 17 per cent.

Meanwhile, 41 per cent of Canadians surveyed reported some sort of pain associated with the side effects. Thirteen per cent say the side effects were “very painful” while 28 per cent say they were “somewhat” so.

Across the country, 59 per cent seem to be on the other side of that; 44 per cent say the side effects were not very painful while 15 per cent say they weren’t painful at all.

Read the full survey:

Legers-North-American-Tracker-March-1st-2021-min

On Monday, Provincial Health Officer Dr. Bonnie Henry announced B.C. would be extending the interval between first and second doses of COVID-19 vaccines to four months. The extension will apply to all three vaccines currently approved in Canada, made by Pfizer-BioNTech, Moderna, and AstraZeneca.

“The important thing that we have learned is that these vaccines work, they give a very high level of protection, and that protection lasts for many months,” Henry said.

Related articles: 

“In combination with the new vaccines that we have available, this gives us a very important and very real benefit to everybody here in B.C. That means we can move everybody up the list and more people will be protected sooner,” B.C.’s top doctor added, noting delaying the second shot “provides very high, real-world protection to more people sooner.”

Word of the extension came as the province unveiled dates for when the most senior British Columbians will begin to have access to the vaccines.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

2020 was the worst year on record for Canada's economy. It shrank by 5.4% – CBC.ca

Published

 on


Canada’s economy shrank by 5.4 per cent last year, official data from Statistics Canada showed Monday, making 2020 the worst year for the country’s economic output since record keeping began.

The data agency said Tuesday that Canada’s gross domestic product — the total value of all goods and services it produced — grew by 2.3 per cent during the last three months of the year, but that was nowhere near enough to offset the record-setting plunge it experienced during the the middle half of 2020.

Since bottoming out in the spring and early summer, economic activity has slowly, steadily grown.

For comparison purposes, Canada’s economy contracted almost twice as much as the U.S. did during the COVID-19 pandemic, despite the U.S. seeing far more cases per capita.

Preliminary data suggests the U.S. economy shrank by 3.5 per cent last year.

More to come

Let’s block ads! (Why?)



Source link

Continue Reading

Business

AstraZeneca, Moderna or Pfizer? Take whichever COVID-19 vaccine you're offered, experts say – The Globe and Mail

Published

 on


A man receives his COVID-19 vaccine at a clinic at Olympic Stadium in Montreal on March 1, 2021.

Paul Chiasson/The Canadian Press

Canadians tempted to shop for a preferred COVID-19 vaccine have been given simple advice from experts who have examined the country’s three available options: Take what is offered as quickly as possible.

The vaccine study and approval processes have swamped the public with numbers about vaccine efficacy, how long immunity may last, details about the difference between innovative and traditional vaccine platforms and shifting schedules for administering doses.

The bottom line for Canadians who are accustomed to using consumer skills to find the best option is simple, according to Tania Watts, an immunologist at the University of Toronto: “I would take what is offered as it decreases your likelihood of severe disease and death.”

Story continues below advertisement

Tracking Canada’s COVID-19 vaccine rollout plans: A continuing guide

Coronavirus tracker: How many COVID-19 cases are there in Canada and worldwide? The latest maps and charts

COVID-19 news: Updates and essential resources about the pandemic

While no direct head-to-head study has been conducted on the COVID-19 vaccines, current data suggest the AstraZeneca shot is just as effective as the Moderna and Pfizer-BioNTech mRNA vaccines at preventing serious illness and death. However, it may be less effective at preventing mild illness.

This difference was enough for an independent committee of experts to draw a distinction between AstraZeneca’s vaccine and the two others in recommendations that were published online Monday by the Public Health Agency of Canada.

The committee determined there were not enough data to recommend the AstraZeneca vaccine for Canadians who are 65 and older, a position also taken by some European countries.

The new recommendations also make clear that those who have previously been prioritized for vaccination, including front-line workers and Indigenous Canadians, should receive the mRNA vaccines as a first choice. In cases where an mRNA vaccine is not available, AstraZeneca should be given when “the advantages of earlier vaccination outweigh the limitations of vaccinating with a less efficacious vaccine” and when the recipient provides informed consent after a discussion about “current local vaccine options.”

When asked if the committee’s more restrictive recommendations for the AstraZeneca vaccine might prompt some people to hold off from taking it when offered, vice-chair Shelley Deeks said, “Vaccine acceptance is one consideration for the committee. … However we also need to ensure that we examine the available data and make evidence-based recommendations.”

Dr. Deeks, a physician and the surveillance medical officer of health for Nova Scotia, added the committee would continue to revise its recommendations as data become available and more vaccines are authorized. This could occur in a matter of days if the Johnson & Johnson single-dose vaccine is approved by Canadian regulators.

The Public Health Agency of Canada responded to the recommendation with a statement saying “the best vaccine for a Canadian is the one they can get.” The agency noted the AstraZeneca shot showed no safety concerns in clinical trials or among seniors already vaccinated in other countries, and is showing some benefits in older populations including reduced chance of hospitalization.

Story continues below advertisement

Last month, University of Edinburgh researchers reported that the vaccination of more than 1.1 million individuals in Scotland with the AstraZeneca and Pfizer-BioNTech vaccines had reduced the risk of hospitalization because of COVID-19 by up to 94 per cent and 85 per cent, respectively.

British Columbia announced Monday it will start a second-track vaccination campaign for essential workers using the refrigerator-stable vaccines such as the AstraZeneca shot. Older and vulnerable populations will continue to receive the Moderna and Pfizer vaccines, which require deep freezing and more preparation.

Bonnie Henry, B.C.’s Provincial Health Officer, said essential workers will have the option to continue waiting their turn for mRNA vaccines if they do not want the AstraZeneca dose.

“There will be a little bit of choice but not a whole lot,” Dr. Henry said. “We encourage people to get the vaccine available to them.”

In Quebec, Daniel Paré, the head of the province’s vaccination program, said Monday that people will not get to choose which vaccine they get, although they will be informed of which dose is coming before they get the needle.

“With a global shortage of vaccine, we use the vaccine that is safe and effective and available,” Mr. Paré told Montreal radio 98.5.

Story continues below advertisement

Dr. Watts at the University of Toronto said concentrating the mRNA vaccines on older and immunocompromised people may make sense because those vaccines have higher efficacy than AstraZeneca’s. People in those categories also have a weaker immune response, she said.

All three vaccines share some unknown factors, such as how long immunity lasts, how long the booster shot can wait and whether they can be used interchangeably in second doses, she said.

Jennifer Gommerman, also an immunologist at the University of Toronto, agreed mRNA vaccines “may be a better choice for groups with less immune response.”

“But for the rest of us, in the name of herd immunity, I would take what’s given as it contributes to the war on COVID,” she said. “All the vaccines prevent severe COVID requiring hospitalization. If you are offered a vaccine, you take it.”

The initial COVID-19 vaccinations in Canada and around the world raise questions about how people react to the shot, how pregnant women should approach it and how far away herd immunity may be. Globe health reporter Kelly Grant and science reporter Ivan Semeniuk discuss the answers. The Globe and Mail

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Let’s block ads! (Why?)



Source link

Continue Reading

Trending